▟ Vinebot intrinsic value, daily

← back

LLY Lilly (Eli)

pharma · valued with opus medium conviction · deep-dived 2026-11-19

STRONG BUY
Intrinsic value$1,856.88
Price (at call)$1,382.75
Margin of safety +34.3%
vs market (rating basis) +88.4%

Incretin juggernaut worth more than its price, but today's 54% margins will fade as pricing normalizes.

The story

Lilly has become the world's most valuable pharma company on the back of tirzepatide (Mounjaro/Zepbound), with orforglipron (oral) and retatrutide extending an incretin franchise that has scale, manufacturing capacity and clinical breadth few rivals can match. TTM revenue of $86B (+33% over FY) and 54% operating margins show the franchise is still in hypergrowth, financed by a heavy $19B capex build-out. Over the next decade it shifts from scarcity pricing to volume-driven maturity: Medicare/government price deals, Novo and next-wave entrants, and eventual tirzepatide patent cliffs in the late 2030s compress economics toward elite-pharma norms.

Growth (0.27), terminal growth, reinvestment, beta and the 12-year horizon stay at prior levels because TTM results confirm the story rather than change it. Target margin rises modestly from 46% to 48% (about 4% relative, not material): TTM margins of 54% prove more operating leverage than expected, but I still model them fading as GLP-1 net prices fall with government deals, oral competition and broader payer coverage. The bigger revenue base and higher margin are why value rises versus my October take.

Value drivers

Revenue growth (Y1)27.0%
Terminal growth4.0%
Forecast horizon12y
Target operating margin48.0%
Years to target margin5
Sales-to-capital1.20
Beta0.95
Failure probability0.0%
Cost of capital (WACC)8.4%
Terminal WACC8.7%

Valuation bridge

PV of explicit FCFF565.35B
PV of terminal value1.12T
Equity value1.65T
÷ shares → per share$1,856.88

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 109.81B 27.0% 53.0% 46.67B 19.45B 27.21B 25.09B
2 137.16B 24.9% 51.7% 56.92B 22.79B 34.13B 29.02B
3 168.46B 22.8% 50.5% 68.23B 26.08B 42.15B 33.05B
4 203.37B 20.7% 49.2% 80.34B 29.10B 51.24B 37.05B
5 241.27B 18.6% 48.0% 92.90B 31.58B 61.31B 40.88B
6 281.19B 16.5% 48.0% 108.27B 33.27B 75.00B 46.11B
7 321.84B 14.5% 48.0% 123.92B 33.87B 90.05B 51.05B
8 361.63B 12.4% 48.0% 139.24B 33.16B 106.08B 55.46B
9 398.78B 10.3% 48.0% 153.54B 30.96B 122.58B 59.10B
10 431.41B 8.2% 48.0% 166.10B 27.19B 138.91B 61.76B
11 457.68B 6.1% 48.0% 176.22B 21.90B 154.32B 63.27B
12 475.99B 4.0% 48.0% 183.27B 15.26B 168.01B 63.51B

Key risks

  • GLP-1 net price erosion from Medicare/Medicaid deals, payer pushback and direct-to-consumer discounting
  • Competitive entry from Novo (CagriSema, oral semaglutide), Amgen, Roche and Chinese biotechs compressing share and price
  • Execution risk on the $19B+/yr manufacturing build-out and on orforglipron/retatrutide launches; late-2030s patent cliff

Catalysts

  • Orforglipron global launch and uptake in primary care
  • Retatrutide phase 3 readouts and outcomes-based label expansions (CV, OSA, MASH, kidney) broadening reimbursement

History

DatePriceIntrinsicMoSRating
2026-11-19$1,382.75 $1,856.88 +34.3% STRONG BUY
2026-10-16$1,251.61 $1,438.22 +14.9% STRONG BUY
2026-09-14$1,115.70 $1,339.64 +20.1% STRONG BUY
2026-08-12$1,215.02 $1,414.33 +16.4% STRONG BUY
2026-07-09$1,215.83 $931.01 -23.4% STRONG BUY
2026-06-23$1,107.08 $780.17 -29.5% BUY